The size of the global HIV therapeutics market is estimated to be growing at a CAGR of 1.4% from 2021 to 2026. The size of the market is predicted to be worth USD 14.75 billion by 2026 from USD 13.76 billion in 2021.
The human immunodeficiency virus (HIV) infection refers to a kind of retrovirus that causes AIDS. HIV affects some immune cells, and it weakens the immune system bringing about loss of capacity to fight against the organisms that cause diseases.
HIV spreads through the exchange of fluids with some infected individual, for example, blood exchange or imparting needles to somebody who is HIV infected. Additionally, HIV can spread from infected mother to child during pregnancy. Some of the symptoms of HIV disease are a slight fever, weakness, swollen glands, cerebral pains, and muscle hurts. Integrase inhibitors section is expected to be the rapidly growing class of antiretroviral medications due to the normal dispatch of extra integrase inhibitors by significant players, such as Gilead Sciences, In. and Merck and Co, Inc.
The growing prevalence of HIV/AIDS leads to increasing HIV therapies, driving growth for the target market.
The availability of efficient therapies is one of the major factors boosting the development of the global HIV therapeutics market. The increasing number of initiatives to control the spread of the HIV epidemic is also propelling the market's growth. Other factors that boost the development of the global HIV therapeutics market are increasing awareness among people, approval of drugs, a robust pipeline of medicines for HIV treatment, and rising healthcare expenditure.
Advancements in diagnostic testing for HIV and the emergence of various testing techniques such as rapid POC testing, ELSIA, viral load testing create lucrative opportunities for the key stakeholders in the market. The HIV therapeutics market is likely to expand further over the forecast period. Increasing preference among people to use self-testing kits and HIV testing kits provide many growth opportunities for the key players in the market. Increasing the adoption of mobile diagnostics tools to detect HIV in developing countries offers growth opportunities for growth in the global HIV therapeutics market.
The social stigma associated with HIV infection is the major challenge for critical players in the market, obstructing the growth of the global HIV therapeutics market. Another major factor that is restraining the market's development is the high costs associated with antiretroviral therapies. Increasing resistance to drugs among patients is expected to be limiting the growth of the global HIV therapeutics market during the forecast period.
Impact of COVID-19 on the global HIV therapeutics market:
The COVID-19 pandemic has harmed the HIV drug market. Furthermore, according to industry experts, the COVID-19 outbreak will have long-term consequences in the coming years. In several nations, the epidemic has resulted in a financial crisis. The human immunodeficiency virus (HIV) is a chronic and life-threatening infection that can be transferred from one person to another through blood or sexual contact. It's a virus that targets CD-4 cells in the immune system, rendering the body resistant to infections and other diseases. Manufacturers' inability to supply ARVs (antiretroviral drugs) on time, the closure of land and air transportation systems, and reduced access to health services within countries resulting from the pandemic are likely to have a detrimental effect on the HIV drugs market in the future.
Furthermore, rescheduling HIV care procedures may result in a potential patient backlog. Until further notice, treatment and lifestyle adjustments may be prescribed in these cases. Moreover, private hospitals and clinics that treat HIV exist in countries such as the United States. Clinics and patients, on the other hand, are encouraged to uphold social distancing norms. As a result, all these factors are expected to affect the HIV drug market in the future.
Market Size Available
2020 to 2026
2021 to 2026
By Type, Application, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, APAC, Latin America, Middle East & Africa
Market Leaders Profiled
GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche and Gilead Sciences
This research report on the global HIV therapeutics market has been segmented and sub-segmented based on type, application, and region.
HIV Therapeutics Market - By Type:
Due to the addition of integrase inhibitors by key players such as Merck & Co. and Gilead Sciences, the product category for integrase inhibitors will expand the fastest. Viral genomic DNA is inserted into the host chromosome by these enzymes during replication. ALLINIs (quinoline-based allosteric IN inhibitors) are quinoline-based allosteric IN inhibitors that potently disrupt HIV-1 replication and are currently in clinical trials.
HIV Therapeutics Market - By Application:
HIV-1 is found in the majority of HIV patients. Both HIV forms weaken the immune system, but HIV-2 develops more slowly and is more difficult to spread than HIV-1. The government's and various NGOs' concerted efforts to provide at-risk individuals with greater access to disease testing and treatment for infected persons are a critical factor driving the HIV-1 market development. Furthermore, the advent of generic medicines, which are less costly and chemically similar to branded drugs, adds to HIV medications.
HIV Therapeutics Market - By Region:
Geographically, North America, trailed by Europe, accounted for the highest market share for the HIV therapeutics market in 2019 due to the affordability and availability of costly treatment for HIV infections and developments in medication treatments in this region. Because of the high incidence and prevalence of HIV/AIDS, increasing awareness about infection, surging government initiatives, and blood donations, the North American human immunodeficiency virus therapeutics market dominated the industry in 2016. In the United States, the human immunodeficiency virus (HIV) therapeutics industry is the world's leading national funding source for the HIV epidemic.
Asia is expected to show a high development rate in the HIV therapeutics market in the next couple of years because of an increasing number of HIV-affected people and expanding research exercises for creating HIV medications and immunizations in the region. Due to the new advances in drugs, the Asia Pacific human immunodeficiency virus therapeutics market will expand profitably. Due to their unique patent laws that lead to the patent protection of essential lifesaving drugs, Asian manufacturers prove to be a tough competitor. Furthermore, the prices are doomed to prevent certain manufacturers from entering the market, thus potentially proliferating the industry in terms of volume.
KEY MARKET PLAYERS:
Some of the noteworthy market participants leading the global HIV therapeutics market profiled in this report are GlaxoSmithKline, Bristol-Myers Squibb, Pfizer, Boehringer Ingelheim, Merck, Hoffmann-La Roche, and Gilead Sciences.
RECENT MARKET HAPPENINGS:
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Drug Class
5.1.2 integrase inhibitor
5.1.3 nucleoside/nucleotide reverse transcriptase inhibitor
5.1.4 non-nucleoside turn around transcriptase inhibitor
5.1.5 HIV-1 protease inhibitor
5.1.6 pharmacokinetic enhancer
5.1.7 passage inhibitor
5.1.8 Y-o-Y Growth Analysis, Drug class
5.1.9 Market Attractiveness Analysis, Drug class
5.1.10 Market Share Analysis, Drug class
5.2.2 HIV Type-1
5.2.3 HIV Type-2
5.2.4 Y-o-Y Growth Analysis, Application
5.2.5 Market Attractiveness Analysis, Application
5.2.6 Market Share Analysis, Application
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 Drug Class
184.108.40.206 HIV TYPE 1&2
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 Drug Class
22.214.171.124 HIV TYPE 1&2
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 Drug Class
184.108.40.206 HIV TYPE 1&2
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.3 Cryo Cell International
8.4 Geron Corporation
8.6 Aastrom Biosciences
8.7 Celgene Corporation
8.9 Cytori Therapeutics
8.10 Retractable Technologies
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures